Geode Capital Management’s Checkmate Pharmaceuticals, Inc. Common Stock CMPI Stock Holding History

Geode Capital Management’s Portfolio CMPI Stock Details CMPI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-41,466	Closed	-$132K	–	5063
2022 Q1	$132K	Buy	41,466 +1,206	+3%	+$3.47K	﹤0.01%	4555
2021 Q4	$115K	Hold	40,260	–	–	﹤0.01%	4689
2021 Q3	$159K	Sell	40,260 -12	-0%	-$62	﹤0.01%	4530
2021 Q2	$240K	Sell	40,272 -63,153	-61%	-$446K	﹤0.01%	4264
2021 Q1	$1.25M	Buy	103,425 +66,595	+181%	+$947K	﹤0.01%	3460
2020 Q4	$537K	Buy	36,830 +6,936	+23%	+$88.4K	﹤0.01%	3567
2020 Q3	$344K	Buy	+29,894	New	+$383K	﹤0.01%	3552

Geode Capital Management's CMPI Position: Q2 2022 in Review

Geode Capital Management sold out of Checkmate Pharmaceuticals, Inc. Common Stock (CMPI) in Q2 2022, closing a stake of 41,466 shares — an estimated $132K sold.

Geode Capital Management first reported a position in CMPI in Q3 2020 and held it in 7 quarters. The position peaked at $1.25M in Q1 2021. 0 funds tracked by Wall St. Rank hold CMPI as of Q2 2022.

Geode Capital Management reported no remaining Checkmate Pharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Geode Capital Management sold 41,466 Checkmate Pharmaceuticals, Inc. Common Stock shares in Q2 2022, an estimated $132K.
Geode Capital Management first reported a position in Checkmate Pharmaceuticals, Inc. Common Stock in Q3 2020 and held it in 7 quarters.
Geode Capital Management's Checkmate Pharmaceuticals, Inc. Common Stock position peaked at $1.25M in Q1 2021.
0 funds tracked by Wall St. Rank held Checkmate Pharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on Geode Capital Management's 13F filing for Q2 2022, filed 12 Aug 2022.